{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Noninvasive plasma biomarker testing provides faster answers: Alicia Algeciras-Schimnich, Ph.D. ","html":"","width":"100%","height":180,"duration":1077,"description":"Alicia Algeciras-Schimnich, Ph.D., discusses how Mayo Clinic Laboratories’ new noninvasive blood test for Alzheimer’s disease identifies the p-tau217 biomarker, which is associated with the accumulation of amyloid beta in the brain. Positive test results can facilitate access to disease-modifying therapies. (00:32):Dr. Algeciras, could you just provide a little bit of background on your role at Mayo Clinic?(01:45):So before we get into the test itself, can you just explain a little bit about the disease state and especially some of the recent changes? (07:39) So can you explain a little bit more about what the results that our clients will receive look like? (10:30) Can you just give a quick overview of how our test is unique compared to those on the market? (12:24) What patients should have this testing performed, Dr. Algeciras and if you have any tips on which patients should not, please include that as well? (14:42) Let's talk now about how those results are used in patient care. (16:31) One more question, just summarize for our listeners what you're most excited about with this new test.","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}